Trading Report: Today, Alder BioPharmaceuticals Inc. (ALDR) Position Maintained by Nationwide Fund Advisors

Today, Alder BioPharmaceuticals Inc. (ALDR) Position Maintained by Nationwide Fund Advisors

Nationwide Fund Advisors continued to hold its stake in shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) during the third quarter, Holdings Channel reports. The firm owned 49,699 shares of the biopharmaceutical company’s stock at the end of the third quarter. Nationwide Fund Advisors owned about 0.10% of Alder BioPharmaceuticals worth $1,629,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. BlackRock Fund Advisors raised its stake in Alder BioPharmaceuticals by 4.2% in the first quarter. BlackRock Fund Advisors now owns 1,136,823 shares of the biopharmaceutical company’s stock worth $27,841,000 after buying an additional 45,908 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Alder BioPharmaceuticals by 85.8% in the second quarter. Bank of New York Mellon Corp now owns 197,768 shares of the biopharmaceutical company’s stock worth $4,938,000 after buying an additional 91,328 shares during the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in Alder BioPharmaceuticals during the second quarter worth $5,990,000. Swiss National Bank raised its stake in Alder BioPharmaceuticals by 72.7% in the second quarter. Swiss National Bank now owns 63,542 shares of the biopharmaceutical company’s stock worth $1,587,000 after buying an additional 26,742 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in Alder BioPharmaceuticals by 35.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 25,400 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 6,600 shares during the last quarter.

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) traded up 4.69% during midday trading on Friday, hitting $26.80. The stock had a trading volume of 297,293 shares. Alder BioPharmaceuticals Inc. has a 12-month low of $15.82 and a 12-month high of $38.74. The company has a 50-day moving average price of $28.00 and a 200-day moving average price of $29.05. The company’s market cap is $1.35 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.15. During the same period last year, the business earned ($0.62) EPS. Equities analysts anticipate that Alder BioPharmaceuticals Inc. will post ($3.13) EPS for the current year.

Several brokerages have commented on ALDR. Aegis set a $41.00 price target on shares of Alder BioPharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Piper Jaffray Cos. set a $47.00 price target on shares of Alder BioPharmaceuticals and gave the company a “buy” rating in a research note on Friday. Zacks Investment Research lowered shares of Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. BMO Capital Markets reiterated a “buy” rating on shares of Alder BioPharmaceuticals in a research note on Tuesday. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $38.00 price target on shares of Alder BioPharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Alder BioPharmaceuticals has a consensus rating of “Buy” and a consensus target price of $43.38.

In related news, insider Mark James Litton sold 6,000 shares of the company’s stock in a transaction on Monday, October 17th. The stock was sold at an average price of $27.50, for a total transaction of $165,000.00. Following the completion of the transaction, the insider now directly owns 99,567 shares in the company, valued at approximately $2,738,092.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Randall C. Schatzman sold 10,000 shares of the company’s stock in a transaction on Monday, November 7th. The stock was sold at an average price of $25.16, for a total value of $251,600.00. Following the transaction, the chief executive officer now owns 124,768 shares of the company’s stock, valued at $3,139,162.88. The disclosure for this sale can be found here. Corporate insiders own 11.50% of the company’s stock.

Alder BioPharmaceuticals Company Profile

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Related posts

Leave a Comment